Matthew D Galsky

Summary

Affiliation: US Oncology
Country: USA

Publications

  1. ncbi Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 69:255-9. 2007
  2. doi Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy
    Matthew D Galsky
    Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Cancer 119:3012-9. 2013
  3. doi Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States
    Alexander C Small
    Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, 1 Gustave L Levy Place, New York, NY, 10029, USA
    World J Urol 31:1211-7. 2013
  4. doi The impact of gender on outcomes in patients with metastatic urothelial carcinoma
    Lindsay Haines
    Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Clin Genitourin Cancer 11:346-52. 2013
  5. doi Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy
    Alexander C Small
    Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York, USA
    Cancer 118:5947-54. 2012
  6. ncbi Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 109:549-55. 2007
  7. doi Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy
    Matthew D Galsky
    Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Cancer 119:3020-6. 2013
  8. doi Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy
    Matthew D Galsky
    Mount Sinai School of Medicine Tisch Cancer Institute, New York, NY 10029, USA
    Clin Genitourin Cancer 9:27-30. 2011
  9. doi Risk of hematologic toxicities in patients with solid tumors treated with everolimus: a systematic review and meta-analysis
    Tomohiro Funakoshi
    Department of Medicine, Beth Israel Medical Center, University Hospital and Manhattan Campus for the Albert Einstein College of Medicine, New York, United States Electronic address
    Crit Rev Oncol Hematol 88:30-41. 2013
  10. doi Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis
    Che Kai Tsao
    Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, 1 Gustave L Levy Place, New York, NY, 10029, USA
    World J Urol 31:1535-9. 2013

Detail Information

Publications61

  1. ncbi Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 69:255-9. 2007
    ..A unifying feature of these malignancies is their aggressive course and poor outcome with standard chemotherapeutic regimens. Given the rarity of these tumors, no prospective data are available to guide management...
  2. doi Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy
    Matthew D Galsky
    Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Cancer 119:3012-9. 2013
    ..The current study was conducted to develop a pretreatment prognostic model for patients with unresectable and/or metastatic urothelial cancer who were treated with first-line, cisplatin-based chemotherapy...
  3. doi Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States
    Alexander C Small
    Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, 1 Gustave L Levy Place, New York, NY, 10029, USA
    World J Urol 31:1211-7. 2013
    ..Our objective was to evaluate trends in the use of NS over the past decade and the socioeconomic factors associated with its use...
  4. doi The impact of gender on outcomes in patients with metastatic urothelial carcinoma
    Lindsay Haines
    Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Clin Genitourin Cancer 11:346-52. 2013
    ..The potential existence of gender-related disparities in patients with metastatic urothelial cancer has not been extensively explored...
  5. doi Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy
    Alexander C Small
    Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York, USA
    Cancer 118:5947-54. 2012
    ..Reasons may include poor functional status, comorbidities, and patient preference. To the authors' knowledge, the prevalence and characteristics of this population have not previously been described...
  6. ncbi Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 109:549-55. 2007
    ..The safety and activity of a dose-dense carboplatin-based regimen in this patient population were explored...
  7. doi Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy
    Matthew D Galsky
    Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Cancer 119:3020-6. 2013
    ....
  8. doi Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy
    Matthew D Galsky
    Mount Sinai School of Medicine Tisch Cancer Institute, New York, NY 10029, USA
    Clin Genitourin Cancer 9:27-30. 2011
    ..We retrospectively evaluated the activity of satraplatin in patients with cisplatin or carboplatin-refractory urothelial carcinoma and demonstrated lack of significant antitumor activity in this population...
  9. doi Risk of hematologic toxicities in patients with solid tumors treated with everolimus: a systematic review and meta-analysis
    Tomohiro Funakoshi
    Department of Medicine, Beth Israel Medical Center, University Hospital and Manhattan Campus for the Albert Einstein College of Medicine, New York, United States Electronic address
    Crit Rev Oncol Hematol 88:30-41. 2013
    ..46, [95% CI 2.58-21.61]) thrombocytopenia, all-grade (RR=1.58, [95% CI 1.25-1.99]) and high-grade (RR=3.92, [95% CI 1.46-10.52]) anemia and all-grade (RR=1.72, [95% CI 1.50-1.97]) and high-grade (RR=2.70, [95% CI 1.86-3.93]) lymphopenia. ..
  10. doi Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis
    Che Kai Tsao
    Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, 1 Gustave L Levy Place, New York, NY, 10029, USA
    World J Urol 31:1535-9. 2013
    ..We evaluated the patterns in the use of CyNx in the cytokine and VEGFR-TKI eras, and the patient characteristics associated with the use of CyNx...
  11. doi Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis
    Tracy Proverbs-Singh
    Division of Hematology Oncology, Tisch Cancer Institute at Mount Sinai Medical Center, Mount Sinai School of Medicine, 1 Gustave L Levy Pl, New York, NY 10029, USA
    J Natl Cancer Inst 104:1837-40. 2012
    ..67% (95% CI = 0.40% to 0.95%), and the RR of ATEs was 1.36 (95% CI = 0.86 to 2.17; P = .19). No increase in ATEs was detected in any prespecified subgroup...
  12. doi Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer
    Che Kai Tsao
    Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Clin Genitourin Cancer 10:15-20. 2012
    ..We sought to determine the impact of using the CKD-EPI equation for estimating renal function on cisplatin eligibility...
  13. ncbi Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Joan and Sanford Weill Medical College of Cornell University, New York, NY 10021, USA
    Invest New Drugs 25:265-70. 2007
    ..The purpose of this single-center phase II study was to determine the activity of pemetrexed administered as second-line therapy in patients with advanced urothelial carcinoma...
  14. doi Metabolic and toxicological considerations of newly approved prostate cancer drugs
    Che Kai Tsao
    The Tisch Cancer Institute, Mount Sinai School of Medicine, Division of Hematology and Medical Oncology, 1 Gustave L Levy Place, New York, NY 10029, USA
    Expert Opin Drug Metab Toxicol 9:835-46. 2013
    ..Understanding of the metabolic and toxicological considerations of each treatment is crucial to the successful management of patients with this lethal disease...
  15. doi Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials
    Tomohiro Funakoshi
    Department of Medicine, Beth Israel Medical Center, University Hospital and Manhattan Campus for the Albert Einstein College of Medicine, New York, United States Electronic address
    Cancer Treat Rev 40:636-47. 2014
    ..We performed a systematic review and meta-analysis to evaluate the safety and efficacy of this therapeutic approach...
  16. doi Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials
    Guru Sonpavde
    Department of Medicine, Section of Medical Oncology, University of Alabama at Birmingham UAB, AL, USA
    Crit Rev Oncol Hematol 87:80-9. 2013
    ..85 (95% CI: 0.58-1.25, p=0.41), respectively. No difference in risk was found based on tumor type, age and trial design. The majority of trials exhibited high quality per Jadad scoring and no heterogeneity or publication bias was found...
  17. doi Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working Group
    Matthew D Galsky
    Mount Sinai School of Medicine, Tisch Cancer Institute, New York, NY 10029, USA
    Cancer 119:1994-8. 2013
    ..There have been no improvements in the treatment of metastatic urothelial cancer in the past several decades. A census of contemporary clinical research in this disease was performed to identify potential barriers and opportunities...
  18. ncbi Advances in the management of muscle-invasive bladder cancer through risk prediction, risk communication, and novel treatment approaches
    Matthew D Galsky
    Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York 10029, USA
    Clin Adv Hematol Oncol 11:86-92. 2013
    ..It is critical that clinicians are able to effectively communicate complex risk-related data to patients to facilitate a shared medical decision...
  19. doi Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes
    Matthew D Galsky
    Division of Hematology and Medical Oncology, Department of Medicine, Director of Genitourinary Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    CA Cancer J Clin 62:299-308. 2012
    ....
  20. doi Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy
    Matthew D Galsky
    Mount Sinai School of Medicine, Tisch Cancer Institute, 1 Gustave L Levy Place, New York, NY 10029, USA
    J Clin Oncol 29:2432-8. 2011
    ..However, a large proportion of patients with metastatic urothelial carcinoma are considered "unfit" for cisplatin. The purpose of this review is to define unfit patients and to identify treatment options for this subgroup of patients...
  21. pmc Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinoma
    Neeraj Agarwal
    Department of Medicine, Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA
    Oncologist 19:915-6. 2014
    ..In this phase Ib/II study, we sought to determine a tolerable dose of lenalidomide in combination with gemcitabine and cisplatin (GCL) in patients with MUC and to explore the safety and activity of this regimen...
  22. doi A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer
    Joshua J Meeks
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Eur Urol 62:523-33. 2012
    ..Muscle-invasive bladder cancer (MIBC) is a disease with a pattern of predominantly distant and early recurrences. Neoadjuvant cisplatin-based combination chemotherapy has demonstrated improved outcomes for MIBC...
  23. doi Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis
    Tomohiro Funakoshi
    Department of Medicine, Beth Israel Medical Center, University Hospital, New York, USA
    Cancer Treat Rev 39:818-30. 2013
    ..However, the incidence and risk of hematologic toxicities have been less well characterized. We performed an up-to-date meta-analysis of trials to evaluate the risk of sunitinib-related hematologic toxicities...
  24. doi Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC)
    Che Kai Tsao
    Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    BJU Int 110:1580-8. 2012
    ....
  25. doi Overcoming castration resistance in prostate cancer
    Che Kai Tsao
    Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York, USA
    Curr Opin Urol 22:167-74. 2012
    ....
  26. doi Trends in the use of cytoreductive nephrectomy in the United States
    Che Kai Tsao
    Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Clin Genitourin Cancer 10:159-63. 2012
    ..However, first-line systemic therapy for mRCC changed in 2005 with FDA approval of VEGFR TKIs. We evaluated the patterns of use of CyNx from 2000 to 2008...
  27. doi A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study
    Robert W Ross
    Division of Solid Tumor Oncology, Department of Medicine, Dana Farber Cancer Institute, Boston, MA, USA
    Lancet Oncol 13:1105-13. 2012
    ..Survival for patients with castration-resistant prostate cancer is highly variable. We assessed the effectiveness of a whole-blood RNA transcript-based model as a prognostic biomarker in castration-resistant prostate cancer...
  28. ncbi The integration of chemotherapy and surgery for bladder cancer
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Natl Compr Canc Netw 3:45-51. 2005
    ..This review summarizes the available literature addressing the role of pelvic lymphadenectomy, neoadjuvant chemotherapy, and adjuvant chemotherapy in the management of patients with muscle-invasive transitional cell carcinoma of bladder...
  29. ncbi Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer
    Matthew D Galsky
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:1439-46. 2005
    ..To evaluate the antitumor activity and safety of the epothilone B analog, ixabepilone, with or without estramustine phosphate (EMP), in chemotherapy-naive patients with progressive castrate metastatic prostate cancer...
  30. ncbi Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials
    Thomas E Hutson
    Genitourinary Oncology Program, Texas Oncology, PA, Baylor Sammons Cancer Center, Dallas, TX 75246, USA
    Clin Genitourin Cancer 5:S31-9. 2006
    ..Combinations of these agents are being evaluated. Clinical trials designed to further assess these and other agents need to be vigorously supported...
  31. ncbi Novel agents for muscle-invasive and advanced urothelial cancer
    Guru Sonpavde
    US Oncology Research, Baylor College of Medicine, Houston, TX 77598, USA
    BJU Int 101:937-43. 2008
    ..Recent and ongoing trials of novel chemotherapeutic and biologic agents are reviewed...
  32. ncbi Current optimal chemotherapy for advanced urothelial cancer
    Guru Sonpavde
    US Oncology Research and Texas Oncology PA, 501 Medical Center Blvd, Webster, TX 77598, USA
    Expert Rev Anticancer Ther 8:51-61. 2008
    ..The profusion of novel biologic agents offers the promise of improved outcomes. A multidisciplinary approach is necessary to make therapeutic advances...
  33. ncbi Outcomes and prognosis in advanced renal cell carcinoma
    Matthew D Galsky
    Genitourinary Oncology Program, US Oncology Research, Las Vegas, Nevada, USA
    Expert Rev Anticancer Ther 7:839-45. 2007
    ..This review will focus on studies that define the outcome and prognosis in advanced renal cell carcinoma...
  34. doi Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics
    Matthew D Galsky
    Translational Oncology Program, US Oncology Research, Dallas, TX, USA
    Invest New Drugs 28:194-8. 2010
    ..To describe a phase II study design to evaluate the activity of novel anti-cancer agents that focuses on molecular pathogenesis rather than tumor histology...
  35. doi Patient selection for phase II trials
    Guru Sonpavde
    Texas Oncology, P A, Dallas, Texas, USA
    Am J Clin Oncol 32:216-9. 2009
    ..Such trials may be superior guides to select regimens for further development than trials that are single-center based with favorable populations...
  36. doi Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium
    Guru Sonpavde
    Texas Oncology, Baylor College of Medicine, Houston, TX 77598, USA
    Lancet Oncol 11:861-70. 2010
    ..A multidisciplinary approach is necessary to make therapeutic advances. This review discusses current second-line therapy and emerging drugs for advanced transitional-cell carcinoma...
  37. doi Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy
    Robert Jotte
    Rocky Mountain Cancer Centers, 10103 Ridgegate Pkwy G 01, Lone Tree, CO 80124, USA
    J Clin Oncol 29:287-93. 2011
    ..This phase II study evaluated the safety and efficacy of single-agent amrubicin versus topotecan in patients with small-cell lung cancer (SCLC) sensitive to first-line platinum-based chemotherapy...
  38. ncbi Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer
    Guru Sonpavde
    Genitourinary Oncology Program, U S Oncology Research, Houston, Texas, USA
    Cancer 110:2628-39. 2007
    ..Recent and ongoing studies of neoadjuvant therapy followed by prostatectomy were reviewed...
  39. doi Is prostate cancer changing?: evolving patterns of metastatic castration-resistant prostate cancer
    Stephanie M Doctor
    Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York
    Cancer 120:833-9. 2014
    ..The pattern of metastatic disease was evaluated in men with mCRPC, as reported in baseline characteristics of prospective clinical trials over 2 decades...
  40. doi Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors
    Matthew D Galsky
    Mount Sinai Medical Center Tisch Cancer Institute, 1 Gustave L Levy Place, New York, NY 10029, USA
    Invest New Drugs 30:695-701. 2012
    ..To explore the activity of lapatinib with a novel trial design focused on the drug target rather than on histology...
  41. doi The emerging role of circulating tumor cell detection in genitourinary cancer
    Alexander C Small
    Division of Hematology Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Urol 188:21-6. 2012
    ..The potential clinical applications of circulating tumor cells include early diagnosis, disease prediction and prognosis, and selection of appropriate therapies...
  42. ncbi The role of taxanes in the management of bladder cancer
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY 10021, USA
    Oncologist 10:792-8. 2005
    ....
  43. pmc Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer
    William K Oh
    Mount Sinai School of Medicine, New York, New York 10029, USA
    Urology 78:626-30. 2011
    ..To evaluate clinical activity and safety of retaspimycin hydrochloride (IPI-504) in patients with castration-resistant prostate cancer (CRPC)...
  44. doi Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer
    Matthew D Galsky
    Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 26:2147-54. 2008
    ..This novel immunoconjugate has shown cytotoxic anti-prostate cancer activity. This study investigated the safety profile, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MLN2704...
  45. doi Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer
    Matthew D Galsky
    Department of Hematology and Medical Oncology, Mount Sinai Medical Center, New York, New York
    Cancer 121:2586-93. 2015
    ..Gemcitabine plus cisplatin (GC) has been adopted as a neoadjuvant regimen for muscle-invasive bladder cancer despite the lack of Level I evidence in this setting...
  46. doi The Impact of Regionalization of Cystectomy on Racial Disparities in Bladder Cancer Care
    Martin F Casey
    Icahn School of Medicine at Mount Sinai, New York, New York
    J Urol 194:36-41. 2015
    ..Regionalization of surgical care has improved the quality of care for patients with bladder cancer. We explored whether regionalization has benefited white and black patients equally...
  47. doi Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer
    Yixuan Gong
    Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York
    Prostate 75:616-27. 2015
    ....
  48. pmc Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors
    Matthew D Galsky
    Division of Hematology Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1 Gustave L Levy Place, New York, NY, 10029, USA
    Cancer Chemother Pharmacol 74:465-71. 2014
    ..The purpose of this phase Ib study was to define the recommended phase 2 dose of the combinations of gemcitabine and cisplatin or gemcitabine and carboplatin plus dovitinib...
  49. doi Is metastatic prostate cancer changing, and how will we know it? It's time for standard nomenclature for nonosseous metastases in clinical trials of patients with metastatic castration resistant prostate cancer
    Che Kai Tsao
    Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
    Eur Urol 66:184-5. 2014
    ..An uniform nomenclature for "deep phenotyping" of metastatic sites in patients with castration-resistant prostate cancer should be mandated in future clinical drug development. ..
  50. doi Bladder cancer: current management and opportunities for a personalized approach
    Matthew D Galsky
    Division of Hematology and Medical Oncology, Mount Sinai School of Medicine, New York, NY, USA
    Mt Sinai J Med 77:587-96. 2010
    ..This review will discuss bladder cancer as a paradigm for the development of personalized cancer medicine, focusing on recent efforts, current challenges, and future opportunities...
  51. ncbi Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder
    Atreya Dash
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 107:506-13. 2006
    ..Renal impairment may be a major factor limiting its use. The current study was designed to determine the proportion of patients ineligible to receive adjuvant cisplatin-based chemotherapy based on inadequate renal function alone...
  52. doi Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer
    Guru Sonpavde
    Department of Medicine, Division of Hematology Oncology, University of Alabama, Birmingham UAB Comprehensive Cancer Center, Birmingham, AL, USA
    BJU Int 114:E25-31. 2014
    ..To investigate the association of radiographic progression defined by Prostate Cancer Working Group (PCWG)-2 guidelines and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC)...
  53. pmc Clinical trial awareness: Changes over time and sociodemographic disparities
    Amanda Leiter
    Department of Medicine, Division of Hematology Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
    Clin Trials 12:215-23. 2015
    ..We sought to define the prevalence of clinical trial awareness in the US population, determine characteristics associated with increased trial awareness, and explore potential disparities in trial awareness...
  54. doi Cisplatin vs. carboplatin-based chemoradiotherapy in patients >65 years of age with stage III non-small cell lung cancer
    Nicole Ezer
    Department of Medicine, Respiratory Division and Respiratory Epidemiology and Clinical Research Unit, McGill University, Montreal, Canada Divisions of General Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, United States Electronic address
    Radiother Oncol 112:272-8. 2014
    ..Combined chemoradiotherapy (CRT) is considered the standard care for unresectable stage III non-small cell lung cancer (NSCLC). There have been limited data comparing outcomes of carboplatin vs. cisplatin-based CRT, particularly in elderly...
  55. pmc Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer
    Che Kai Tsao
    Division of Hematology and Medical Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Clin Med Insights Oncol 5:163-9. 2011
    ..In this review, we examine the clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer, as well as rationale and direction of future therapeutic investigation...
  56. ncbi Violaceous exanthem as a manifestation of metastatic prostate cancer in skin
    Susan F Slovin
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 67:420. 2006
  57. ncbi Problems with the randomized discontinuation design
    Guru Sonpavde
    J Clin Oncol 24:4669-70; author reply 4670-1. 2006
  58. ncbi Germ-cell tumors
    Varuni Kondagunta
    N Engl J Med 357:1773; author reply 1773-4. 2007
  59. ncbi Bladder cancer "adjuvant-lite": tastes great (works as well) and less filling (less toxic)?
    Matthew D Galsky
    J Clin Oncol 23:4823-6. 2005
  60. doi Trial design for metastatic castration-resistant prostate cancer
    Guru Sonpavde
    J Clin Oncol 26:3647-8; author reply 3648-9. 2008
  61. ncbi A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy
    Jonathan E Rosenberg
    Division of Hematology Oncology, University of California San Francisco, San Francisco, California 94115, USA
    Cancer 106:58-62. 2006
    ..Clinical cross-resistance of ixabepilone and taxanes in HRPC is unknown...